Abstract
Rare diseases form the bulk of the financial expenditure of any developing or developed economy. Among the various rare diseases, paediatric neuromuscular disorders form a major portion, with a worldwide survey estimating a prevalence of 1 in 3500 individuals. In a lower middle-income country (LMIC) like India, malnutrition still accounts for most of the under-5 mortality. However, the economic burden of rare paediatric neuromuscular disorders cannot be underestimated. The treating physician should have a basic understanding of how to approach a child presenting with weakness and how to utilise the available tests which are affordable in an LMIC setting. History and examination still form the core, and with new diagnostic methods like next-generation sequencing, more and more rare disorders are getting diagnosed. It is important for the treating physician to know about basic supportive care, recent advancements, and available treatment options for these conditions. With exciting new treatment options being available for these disorders, the perception of these diseases as being not treatable is gradually changing. This review aims to be of guidance to clinicians from an LMIC setting like India and to empower them to manage such rare paediatric neuromuscular disorders.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angelis A, Tordrup D and Kanavos P 2015 Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 119 964–979
Barohn RJ, Dimachkie MM and Jackson CE 2014 A pattern recognition approach to patients with a suspected myopathy. Neurol. Clin. 32 569–593
Birnkrant DJ, Bushby K, Bann CM, et al. 2018 Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 17 347–361
Bosch AM, Stroek K, Abeling NG, et al. 2012 The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. Orphanet J. Rare Dis. 7 83
Chu ML and Moran E 2018 The limb-girdle muscular dystrophies: Is treatment on the horizon? Neurotherapeutics 4 849–862
Dowling JJ, Gonorazky DH, Cohn RD, et al. 2017 Treating paediatric neuromuscular disorders: The future is now. Am. J. Med. Genet. A 176 804–841
Emery AE 1991 Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscul. Disord. 1 19–29
Engel AG, Shen XM, Selcen D, et al. 2015 Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 14 420–434
Ferreira CR 2019 The burden of rare diseases. Am. J. Med. Genet. A 179 885–892
Gineste C and Laporte J 2023 Therapeutic approaches in different congenital myopathies. Curr. Opin. Pharmacol. 68 102328
Hall JG, Powers EK, Mcllvaine RT, et al. 1978 The frequency and financial burden of genetic disease in a paediatric hospital. Am. J. Med. Genet. 1 417–436
Heron M 2018 Deaths: Leading causes for 2016. Natl. Vital Stat. Rep. 67 1–77
Jackson CE 2008 A clinical approach to muscle diseases. Semin. Neurol. 28 228–240
Katragadda S, Hall TO, Bettadapura R, et al. 2021 Determining cost-optimal next-generation sequencing panels for rare disease and pharmacogenomics testing. Clin. Chem. 67 1122–1132
Matthews E, Brassington R, Kuntzer T, et al. 2016 Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 5 CD003725
McDonald CM 2012 Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases. Phys. Med. Rehabil. Clin. N. Am. 23 495–563
National Policy for Rare Disease, NPRD 2021 https://main.mohfw.gov.in/sites/default/files/Final%20NPRD%2C%202021.pdf
National Organization for Rase Disease, NORD 2023 Rare disease database https://rarediseases.org/rare-diseases/
Orphanet Report Series – Prevalence of rare diseases: Bibliographic data 2022 http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_diseases.pdf
Pasnoor M and Dimachkie MM 2019 Approach to muscle and neuromuscular junction disorders. Continuum 25 1536–1563
Pisciotta C, Saveri P and Pareyson D 2021 Challenges in treating Charcot-Marie-Tooth disease and related neuropathies: current management and future perspectives. Brain Sci. 11 1447
Ricci FS, D’Alessandro R, Vacchetti M, et al. 2022 Improving recognition of treatable rare neuromuscular disorders in primary care: A pilot feasibility study. Children 9 1063
Schorling DC, Pechmann A and Kirschner J 2020 Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J. Neuromuscul. Dis. 7 1–13
Soneda A, Teruya H, Furuya N, et al. 2012 Proportion of malformations and genetic disorders among cases encountered at a high-care unit in a children’s hospital. Eur. J. Pediatr. 171 301–305
Statland JM and Barohn RJ 2013 Muscle channelopathies: the nondystrophic myotonias and periodic paralyses. Continuum 19 1598–1614
Strehle EM 2009 Long-term management of children with neuromuscular disorders. J. Pediatr. 85 379–384
Suthar R and Patil AN 2021 Spinal muscular atrophy therapeutics in India: Parental hopes and despair! Ann. Neurosci. 28 112–113
Swaminathan S, Hemalatha R, Pandey A, et al. 2019 The burden of child and maternal malnutrition and trends in its indicators in the states of India: the Global Burden of Disease Study 1990–2017. Lancet Child Adolesc. Health 3 855–870
Teoh HL, Sampaio H, Roscioli T, et al. 2016 Approaches to genetic diagnosis in neuromuscular conditions in the era of next generation sequencing. J. Neurol. Neurosurg. Psychiatry 87 1384–1385
The Drugs and Cosmetics Act, 1940 (23 of 1940) and the Drugs and Cosmetics Rules 1945. 2016. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf
World Health Organization 2022 ICD-11: International classification of diseases. https://icd.who.int/
Yao S, Chen Z, Yu Y, et al. 2021 Current pharmacological strategies for Duchenne muscular dystrophy. Front. Cell Dev. Biol. 9 689533
Yasha TC, Sharma S, Gayathri N, et al. 2022 Hereditary neuropathies: Genetics and utility of nerve biopsy. Indian J. Pathol. Microbiol. 65 318–328
Yoon PW, Olney RS, Khoury MJ, et al. 1997 Contribution of birth defects and genetic diseases to paediatric hospitalizations. A population-based study. Arch. Pediatr. Adolesc. Med. 15 1096–1103
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: Alok Bhattacharya
This article is part of the Topical Collection: The Rare Genetic Disease Research Landscape in India.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mahesan, A., Kamila, G. & Gulati, S. Rare paediatric disorders in Indian healthcare settings with focus on neuromuscular disorders: Diagnostic and management challenges. J Biosci 49, 15 (2024). https://doi.org/10.1007/s12038-023-00403-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12038-023-00403-w